CJC-1295 & Ipamorelin

What Is CJC-1295? Research Overview

Reviewed by our laboratory team · Last updated 2026-07-03

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue originally developed by ConjuChem. It exists in two research forms: with Drug Affinity Complex (DAC), which extends half-life via albumin binding, and without DAC (also called Modified GRF 1-29), which has a much shorter half-life.

Key facts

Class
GHRH analogue
Original developer
ConjuChem
Forms
CJC-1295 with DAC; CJC-1295 no DAC (Mod GRF 1-29)
Status
Investigational — not approved

GHRH context

Natural GHRH is a 44-residue hypothalamic hormone. CJC-1295 is based on the first 29 residues (GRF 1-29) with amino-acid substitutions for stability, plus optional DAC lipid tag for albumin binding.

Research use

Research literature on CJC-1295 examines GH pulsatility, IGF-1 responses, and receptor-level pharmacology, largely in early-phase human PK studies and animal models.

Research material referenced

CJC-1295 + Ipamorelin 5+5mg — third-party HPLC tested

View — £36.99

Extended research context

The CJC-1295 & Ipamorelin deep dive

Deep dive: why CJC-1295 and Ipamorelin are studied together

CJC-1295 is a modified GHRH (growth-hormone-releasing hormone) analogue; Ipamorelin is a selective growth-hormone secretagogue that binds the ghrelin receptor (GHS-R1a). In pituitary-cell research models the two act on independent pathways whose downstream effect converges on GH release — CJC-1295 amplifies the endogenous GHRH signal while Ipamorelin adds a separate ghrelin-pathway stimulus. That's why supplier catalogues frequently package them together as a research reference blend.

DAC vs no-DAC: which CJC-1295 is which

'CJC-1295 with DAC' contains a Drug Affinity Complex (a Lys-maleimide moiety) that binds serum albumin and extends half-life to several days. 'CJC-1295 no-DAC' (also called Modified GRF 1-29) lacks the linker and clears in minutes. These are pharmacologically different peptides. A CoA must specify which form is in the vial; mass differs (~3,367 Da with DAC vs ~3,367 minus linker for no-DAC).

Ipamorelin's selectivity profile

Unlike earlier GHS-R agonists (e.g. GHRP-6), Ipamorelin was engineered for minimal cross-activity at cortisol- and prolactin-releasing pathways in research models. That receptor selectivity is why it is the reference secretagogue for controlled pituitary-cell studies.

Research applications

  • Pituitary-cell GH-release assays (comparator vs GHRH and hexarelin)
  • Half-life comparison studies: DAC vs no-DAC CJC-1295 forms
  • Ghrelin-receptor binding assays for Ipamorelin analogue development
  • Analytical HPLC method development for lipidated GHRH analogues
  • Stability testing under refrigerated storage

Handling checklist

  • Store lyophilised at −20 °C long-term
  • Reconstitute in bacteriostatic water; both peptides dissolve readily
  • Aliquot immediately, refrigerate at 2–8 °C, use within 28 days
  • Confirm salt form and DAC/no-DAC status on CoA before starting a study
  • Do not use for human administration — research reference only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

Confusing DAC and no-DAC CJC-1295

Fix: Check the CoA — the two have very different pharmacokinetics.

Assuming Ipamorelin acts on GHRH receptors

Fix: It binds the ghrelin receptor (GHS-R1a) — a separate pathway from CJC-1295.

Storing reconstituted solution at room temperature

Fix: Refrigerate 2–8 °C after reconstitution.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Related questions researchers ask

  • Is CJC-1295 the same as Modified GRF 1-29?
  • What is the difference between DAC and no-DAC CJC-1295?
  • Does Ipamorelin raise cortisol?
  • Why are CJC-1295 and Ipamorelin blended together?
  • How long is the half-life of CJC-1295 with DAC?

Frequently asked questions

Is CJC-1295 approved?
No — it is investigational and not approved by any major regulator.
Why two forms?
DAC extends half-life to about a week; without DAC the half-life is minutes.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab (external, rel="nofollow").

More CJC-1295 & Ipamorelin articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.